德谷门冬双胰岛素注射液联合二甲双胍治疗2型糖尿病患者的疗效及对其血糖水平、不良反应的影响研究

Study on efficacy of insulin degludec and insulin aspart injection combined with metformin on patients with type 2 diabetes mellitus and its influence on blood glucose level and adverse reactions

目的分析2型糖尿病患者使用德谷门冬双胰岛素注射液联合二甲双胍治疗后的血糖水平、不良反应,判断其治疗效果。方法选择76例2型糖尿病患者为研究对象,随机分成对照组和观察组,每组38例。对照组患者给予二甲双胍治疗,观察组在对照组基础上给予德谷门冬双胰岛素注射液治疗。比较两组治疗前后的血糖[空腹血糖(FPG)、糖化血红蛋白(HbA1c)、餐后2 h血糖(2 h PG)]水平,不良反应发生率,治疗前后的胰岛功能[空腹胰岛素(FINS)、胰岛β细胞功能指数(HOMA-β)、胰岛素抵抗指数(HOMA-IR)]、疗效。结果两组治疗后FPG、HbA1c、2 h PG均低于治疗前,差异具有统计学意义(P<0.05);观察组治疗后FPG(6.30±1.12)mmol/L、HbA1c(6.37±0.49)%、2 h PG(8.05±1.12)mmol/L明显低于对照组的(7.29±1.34)mmol/L、(7.32±0.83)%、(9.62±1.70)mmol/L,差异具有统计学意义(P<0.05)。与对照组的23.68%相比,观察组治疗期间不良反应发生率5.26%明显较低,差异具有统计学意义(P<0.05)。治疗后,两组患者的FINS、HOMA-β、HOMA-IR均较治疗前改善,且观察组患者FINS(14.03±1.52)mU/L、HOMA-β(80.35±10.36)明显高于对照组的(11.52±1.30)mU/L、(72.15±9.21),HOMA-IR(3.19±0.21)明显低于对照组的(3.81±0.42),差异具有统计学意义(P<0.05)。与对照组的73.68%相比,观察组患者治疗总有效率92.11%明显较高,差异具有统计学意义(P<0.05)。结论经过德谷门冬双胰岛素联合二甲双胍治疗后,2型糖尿病患者的血糖水平明显改善,安全性高,总体疗效较好,对于治疗2型糖尿病有着重大意义。

Objective To analyze the blood glucose level and adverse reactions of patients with type 2 diabetes mellitus after taking insulin degludec and insulin aspart injection combined with metformin,and to judge the therapeutic effect.Methods 76 patients with type 2 diabetes mellitus were selected as the research subjects.They were randomly divided into a control group and an observation group,with 38 cases in each group.The control group was treated with metformin,and the observation group was treated with insulin degludec and insulin aspart injection based on the control group.Both groups were compared in terms of blood glucose[fasting plasma glucose(FPG),glycated hemoglobin(HbA1c),2 h postprandial plasma glucose(2 h PG)]level,incidence of adverse reactions,islet function[fasting insulin(FINS),homeostasis model assessment ofβcell function(HOMA-β),homeostasis model assessment of insulin resistance index(HOMA-IR)]and efficacy.Results After treatment,FPG,HbA1c,and 2 h PG in both groups were lower than those before treatment,and the difference was statistically significant(P<0.05).After treatment,the observation group had FPG of(6.30±1.12)mmol/L,HbA1c of(6.37±0.49)%,and 2 h PG of(8.05±1.12)mmol/L,which were significantly lower than(7.29±1.34)mmol/L,(7.32±0.83)%,and(9.62±1.70)mmol/L of the control group,and the difference was statistically significant(P<0.05).Compared with 23.68%in the control group,the incidence of adverse reactions during treatment in the observation group was significantly lower at 5.26%,and the difference was statistically significant(P<0.05).After treatment,the FINS,HOMA-β,HOMA-IR in both groups were improved compared with those before treatment;the observation group had FINS of(14.03±1.52)mU/L and HOMA-βof(80.35±10.36),which were significantly higher than(11.52±1.30)mU/L and(72.15±9.21)in the control group;HOMA-IR of(3.19±0.21)in the observation group was significantly lower than(3.81±0.42)in the control group;the difference was statistically significant(P<0.05).Compared with 73.68%in the control group,the total effective rate of treatment in the observation group significantly higher at 92.11%,and the difference was statistically significant(P<0.05).Conclusion After the treatment of insulin degludec and insulin aspart injection combined with metformin,the blood glucose level of type 2 diabetes mellitus patients is significantly improved,with high safety and good overall efficacy,which is of great significance for the treatment of type 2 diabetes mellitus.